Veterinary Medicines

Nafpenzal DC, intramammaarsuspensioon kinnislehmadele

Authorised
  • Benzylpenicillin procaine
  • Dihydrostreptomycin
  • Nafcillin
Download as PDF

Product identification

Medicine name:
Nafpenzal DC, intramammaarsuspensioon kinnislehmadele
Active substance:
  • Benzylpenicillin procaine
  • Dihydrostreptomycin
  • Nafcillin
Target species:
  • Cattle (dry cow)
Route of administration:
  • Intramammary use

Product details

Active substance and strength:
  • Benzylpenicillin procaine
    300.00
    milligram(s)
    /
    1.00
    Syringe
  • Dihydrostreptomycin
    100.00
    milligram(s)
    /
    1.00
    Syringe
  • Nafcillin
    100.00
    milligram(s)
    /
    1.00
    Syringe
Pharmaceutical form:
  • Intramammary suspension
Withdrawal period by route of administration:
  • Intramammary use
    • Cattle (dry cow)
      • Meat and offal
        14
        day
      • Milk
        36
        hour
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ51RC23
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Estonia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • INTERVET INTERNATIONAL B.V.
Responsible authority:
  • RAVIMIAMET
Authorisation number:
  • 1189
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Estonian (PDF)
Published on: 24/01/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."